دورية أكاديمية
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
العنوان: | Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. |
---|---|
المؤلفون: | Fizazi K; Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. fizazi@igr.fr, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ |
المصدر: | British journal of cancer [Br J Cancer] 2002 May 20; Vol. 86 (10), pp. 1555-60. |
نوع المنشور: | Clinical Trial; Clinical Trial, Phase II; Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Print ISSN: 0007-0920 (Print) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis. |
مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Germinoma/*drug therapy , Seminoma/*drug therapy , Testicular Neoplasms/*drug therapy, Adolescent ; Adult ; Anemia, Refractory, with Excess of Blasts/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biomarkers, Tumor/blood ; Bleomycin/administration & dosage ; Bleomycin/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dactinomycin/administration & dosage ; Dactinomycin/adverse effects ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Gastrointestinal Diseases/chemically induced ; Germinoma/mortality ; Germinoma/pathology ; Germinoma/secondary ; Hematologic Diseases/chemically induced ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Male ; Methotrexate/administration & dosage ; Methotrexate/adverse effects ; Middle Aged ; Peripheral Nervous System Diseases/chemically induced ; Prognosis ; Prospective Studies ; Remission Induction ; Seminoma/mortality ; Seminoma/pathology ; Seminoma/secondary ; Survival Analysis ; Survival Rate ; Testicular Neoplasms/mortality ; Testicular Neoplasms/pathology ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects |
مستخلص: | Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this phase II study was to assess the efficacy and toxicity of a dose-dense alternating chemotherapy regimen in this subset of patients. High volume non-seminomatous germ-cell tumours was defined as follows: at least two sites of non pulmonary metastases, an extragonadal primary tumour, a serum human chorionic gonadotropin level higher than 10 000 mIU x ml(-1), or a alpha-foetoprotein level higher than 2000 mIU ml(-1). Patients who fulfilled these criteria were treated with the so-called BOP-CISCA-POMB-ACE regimen (bleomycin, vincristine, and cisplatin; cisplatin, cyclophosphamide, and doxorubicin; cisplatin, vincristine, methotrexate, and bleomycin; etoposide, dactinomycin, and cyclophosphamide) plus granulocyte colony-stimulating factor. A total of 58 patients were enrolled. Patients were retrospectively classified according to the International Germ-Cell Cancer Consensus Group classification; 38 patients (66%) had poor-prognosis disease and 19 patients (33%) had intermediate-prognosis. Patients received a median of 2.5 courses (range 0.25 to five courses) of the BOP-CISCA-POMB-ACE regimen. Forty-two patients (72.4%) had a complete response to therapy. With a median follow-up time of 31 months, the 3-year progression-free survival rate was 71% (95% confidence interval, 60 to 84%) and the 3-year overall survival rate was 73% (95% confidence interval: 62 to 86%). The 3-year PFS rates were 83% (95% confidence interval: 68 to 100%) in the intermediate-prognosis group and 65% (95% confidence interval: 51 to 82%) in the poor-prognosis group. Early side effects included mainly grade 4 haematologic toxicity (neutropaenia in 79% of patients, thrombocytopaenia in 69%, anaemia in 22%), grade 4 stomatitis (19%), and four early deaths (7% of patients), at least partially related to toxicity. The dose-dense BOP-CISCA-POMB-ACE regimen is highly active in patients with non-seminomatous germ-cell tumours classified as intermediate-prognosis or poor-prognosis according to the International Germ-Cell Cancer Consensus Group. Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients. (comCopyright 2002 Cancer Research UK) |
References: | Crit Rev Oncol Hematol. 1996 Apr;22(3):229-63. (PMID: 8793277) Cancer. 1977 Apr;39(4):1372-81. (PMID: 856437) N Engl J Med. 1987 Jun 4;316(23):1435-40. (PMID: 2437455) J Clin Oncol. 1988 Jun;6(6):1031-40. (PMID: 2453619) Control Clin Trials. 1989 Mar;10(1):1-10. (PMID: 2702835) Bull Cancer. 1990;77(2):169-80. (PMID: 2156588) Cancer Res. 1990 Sep 15;50(18):5904-10. (PMID: 1697503) Ann Oncol. 1991 Mar;2(3):197-202. (PMID: 1710481) Ann Oncol. 1991 Mar;2(3):203-11. (PMID: 1710482) J Clin Oncol. 1991 Jul;9(7):1163-72. (PMID: 1710655) Eur Urol. 1992;21(4):287-93. (PMID: 1333957) Eur Urol. 1993;23(1):213-7; discussion 218. (PMID: 8386652) J Clin Oncol. 1995 Jan;13(1):283-92. (PMID: 7799032) J Clin Oncol. 1995 Jan;13(1):87-92. (PMID: 7528272) Eur J Cancer. 1994;30A(11):1607-11. (PMID: 7530470) N Engl J Med. 1997 Jul 24;337(4):242-53. (PMID: 9227931) Ann Oncol. 1997 May;8(5):477-83. (PMID: 9233528) J Clin Oncol. 1998 Feb;16(2):692-701. (PMID: 9469359) J Clin Oncol. 1998 Feb;16(2):725-32. (PMID: 9469363) J Clin Oncol. 1998 Feb;16(2):799-800. (PMID: 9469373) J Clin Oncol. 1998 Apr;16(4):1287-93. (PMID: 9552027) Br J Cancer. 1998 Sep;78(6):828-32. (PMID: 9743309) Ann Oncol. 1999 Mar;10(3):289-93. (PMID: 10355572) J Clin Oncol. 1999 Nov;17(11):3450-6. (PMID: 10550141) Ann Oncol. 2000 Feb;11(2):133-49. (PMID: 10761747) Eur J Cancer. 2000 Jul;36(11):1389-94. (PMID: 10899652) Ann Oncol. 2000 Sep;11(9):1115-20. (PMID: 11061604) Cancer. 1982 Oct 15;50(8):1629-35. (PMID: 6288220) Cancer. 1984 Jan 15;53(2):203-9. (PMID: 6197154) Cancer. 1984 Mar 1;53(5):1029-35. (PMID: 6198064) J Clin Oncol. 1985 Mar;3(3):326-35. (PMID: 2579213) Am J Med. 1986 Aug;81(2):219-28. (PMID: 2426944) J Clin Oncol. 2001 May 1;19(9):2534-41. (PMID: 11331333) Cancer. 2001 Sep 15;92(6):1460-7. (PMID: 11745223) Ann Oncol. 2002 Jan;13(1):125-34. (PMID: 11863094) J Clin Oncol. 1997 Feb;15(2):594-603. (PMID: 9053482) |
المشرفين على المادة: | 0 (Biomarkers, Tumor) 11056-06-7 (Bleomycin) 1CC1JFE158 (Dactinomycin) 5J49Q6B70F (Vincristine) 6PLQ3CP4P3 (Etoposide) 80168379AG (Doxorubicin) 8N3DW7272P (Cyclophosphamide) Q20Q21Q62J (Cisplatin) YL5FZ2Y5U1 (Methotrexate) |
SCR Protocol: | BOP-CISCA-POMB-ACE regimen |
تواريخ الأحداث: | Date Created: 20020627 Date Completed: 20020802 Latest Revision: 20181113 |
رمز التحديث: | 20240627 |
مُعرف محوري في PubMed: | PMC2746595 |
DOI: | 10.1038/sj.bjc.6600272 |
PMID: | 12085204 |
قاعدة البيانات: | MEDLINE |
تدمد: | 0007-0920 |
---|---|
DOI: | 10.1038/sj.bjc.6600272 |